{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:15:30Z","timestamp":1791270930457,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.ctrv.2009.10.006","type":"journal-article","created":{"date-parts":[[2009,11,28]],"date-time":"2009-11-28T09:26:39Z","timestamp":1259400399000},"page":"69-74","source":"Crossref","is-referenced-by-count":96,"title":["Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis"],"prefix":"10.1016","volume":"36","author":[{"given":"Davide","family":"Mauri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Kamposioras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamprini","family":"Tsali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalini","family":"Bristianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis","family":"Valachis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Karathanasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Georgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos P.","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.ctrv.2009.10.006_bib1","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/jnci\/djn414","article-title":"Multiple treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer","volume":"100","author":"Mauri","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2009.10.006_bib2","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.2002.07.058","article-title":"Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer","volume":"20","author":"Esteva","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.10.006_bib3","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1200\/JCO.1998.16.6.2164","article-title":"Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer","volume":"16","author":"Hainsworth","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.10.006_bib4","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1200\/JCO.1994.12.7.1458","article-title":"Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis","volume":"12","author":"Tomiak","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.10.006_bib5","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1200\/JCO.2000.18.6.1212","article-title":"Docetaxel administered on a weekly basis for metastatic breast cancer","volume":"18","author":"Burstein","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.10.006_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.ctrv.2009.10.006_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ctrv.2009.10.006_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"10.1016\/j.ctrv.2009.10.006_bib9","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.ctrv.2009.10.006_bib10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.ctrv.2009.10.006_bib11","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/cncr.23321","article-title":"Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer","volume":"112","author":"Rivera","year":"2008","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2009.10.006_bib12","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/annonc\/mdh349","article-title":"A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer","volume":"15","author":"Tabernero","year":"2004","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2009.10.006_bib13","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"Seidman","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2009.10.006_bib14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10549-008-0047-9","article-title":"A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study","volume":"115","author":"Fountzilas","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.ctrv.2009.10.006_bib15","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bjc.6603395","article-title":"Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study","volume":"95","author":"Frasci","year":"2006","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2009.10.006_bib16","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.ejca.2006.05.001","article-title":"Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study","volume":"42","author":"Khoo","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2009.10.006_bib17","article-title":"Weekly docetaxel vs every 3-week in advanced breast cancer: results of a pilot comparative study","volume":"21","author":"Sedky","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl. 4","key":"10.1016\/j.ctrv.2009.10.006_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1359-6349(07)70868-6","article-title":"Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer","volume":"5","author":"Gradishar","year":"2007","journal-title":"Eur J Cancer"},{"issue":"16S, June 1 Suppl.","key":"10.1016\/j.ctrv.2009.10.006_bib19","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/jco.2005.23.16_suppl.580","article-title":"Weekly cisplatin\u2013epirubicin\u2013paclitaxel with G-CSF support (PET) vs. triweekly epirubicin\u2013paclitaxel (ET) in metastatic breast cancer (MBC)","volume":"23","author":"Frasci","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.10.006_bib20","article-title":"Multicenter, 3-arm randomized study of high-dose weekly paclitaxel (HDWP) versus standard-dose weekly paclitaxel (SDWP) for metastatic breast cancer (MBC)","volume":"21","author":"Sikov","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2009.10.006_bib21","first-page":"S70","article-title":"A phase III study on the efficacy and safety of docetaxel, every three weeks or as a weekly regimen in patients with metastatic breast cancer","volume":"106","author":"Willemse","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"22","key":"10.1016\/j.ctrv.2009.10.006_bib22","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2008.18.5397","article-title":"Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer","volume":"27","author":"Gradishar","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2009.10.006_bib23","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdn670","article-title":"Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined","volume":"20","author":"Saad","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2009.10.006_bib24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0163278702025001006","article-title":"To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data","volume":"25","author":"Stewart","year":"2002","journal-title":"Eval Health Prof"},{"key":"10.1016\/j.ctrv.2009.10.006_bib25","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/bjc.1998.339","article-title":"Individual patient data metanalysis in cancer","volume":"77","author":"Clarke","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2009.10.006_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(97)08468-7","article-title":"Summing up evidence: one answer is not always enough","volume":"351","author":"Lau","year":"1998","journal-title":"Lancet"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737209001595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737209001595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T03:17:31Z","timestamp":1558667851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737209001595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0305737209001595"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2009.10.006","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}